{
  "meta": {
    "title": "Tb_And_Ntep",
    "url": "https://brainandscalpel.vercel.app/tb-and-ntep-0b445439.html",
    "scrapedAt": "2025-11-30T11:18:54.272Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Cough >3 weeks & 3 sputum samples</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Cough >3 weeks & 2 sputum samples</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Cough >2 weeks & 2 sputum samples</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Cough >2 weeks & 3 sputum samples</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Choose the diagnostic criteria for detecting TB under RNTCP</span></p>",
      "unique_key": "DT1230723",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230723,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The <strong>Revised National Tuberculosis Control Programme (RNTCP)</strong>, now under the <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, defines the diagnostic criteria for TB suspects based on cough duration and sputum sample collection.</p>\r\n<ul>\r\n<li><strong>Cough for more than 2 weeks</strong> is the standard threshold to suspect pulmonary TB.</li>\r\n<li><strong>Two sputum samples</strong> are collected for smear microscopy - one \"spot\" sample and one \"early morning\" sample.</li>\r\n<li>If the first sample is positive, the patient is diagnosed as microbiologically confirmed TB. If negative, further testing with CXR and CBNAAT may be required as per algorithm.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>A) Cough &gt;3 weeks &amp; 3 sputum samples:</strong> Duration of &gt;3 weeks is longer than required; 3 samples are not standard under RNTCP unless initial smears are negative and suspicion remains.</p>\r\n<p><strong>B) Cough &gt;3 weeks &amp; 2 sputum samples:</strong> Duration criterion (&gt;3 weeks) is incorrect; RNTCP specifies &gt;2 weeks.</p>\r\n<p><strong>D) Cough &gt;2 weeks &amp; 3 sputum samples:</strong> Duration is correct, but the standard number of sputum samples is 2, not 3.</p>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">1</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">2</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">3</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">How many sputum samples are needed for the diagnosis of TB?</span></p>",
      "unique_key": "DT1230724",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230724,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The Revised National Tuberculosis Control Programme (<strong>RNTCP</strong>) recommends collecting <strong>two sputum samples</strong> for the initial diagnosis of tuberculosis. This approach provides a good balance between diagnostic accuracy and feasibility in field conditions.</p>\r\n<ul>\r\n<li><strong>Two sputum samples</strong> are adequate to detect <em>Mycobacterium tuberculosis</em> in most cases because the shedding of bacilli in sputum can be intermittent, and multiple samples improve the detection rate.</li>\r\n<li>Under the program, the usual practice is:\r\n<ol>\r\n<li><strong>Spot sample:</strong> Collected when the patient first presents to the health facility.</li>\r\n<li><strong>Early morning sample:</strong> Collected the next morning, which often contains a higher bacillary load.</li>\r\n</ol>\r\n</li>\r\n<li>If both samples are negative but there is strong clinical suspicion, further diagnostic tests such as <strong>CBNAAT</strong>, culture, or radiological evaluation are performed.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>1 (Option A):</strong> Although TB can sometimes be detected with a single sputum sample, RNTCP recommends two samples to reduce the risk of false negatives.</p>\r\n<p><strong>3 (Option C):</strong> Three samples may slightly increase sensitivity but are not part of the standard initial diagnostic protocol under RNTCP.</p>\r\n<p><strong>4 (Option D):</strong> Collecting four sputum samples is excessive, impractical, and not recommended in routine practice.</p>",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">INH</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Rifampicin</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Ethambutol</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Streptomycin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which anti-TB drug causes visual disturbances?</span></p>",
      "unique_key": "DT1230725",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230725,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Ethambutol is the anti-tubercular drug most commonly associated with <strong>visual disturbances</strong>, particularly <strong>optic neuritis</strong>.</p>\r\n<ul>\r\n<li><strong>Adverse effect:</strong> Optic neuritis can lead to blurred vision, decreased visual acuity, and loss of red-green color discrimination.</li>\r\n<li><strong>Risk factors:</strong> Higher doses and prolonged duration of therapy increase the risk.</li>\r\n<li><strong>Prevention:</strong> Regular monitoring of visual acuity and color vision during therapy helps in early detection and prevention of irreversible damage.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>INH (Option A):</strong> Known for hepatotoxicity and peripheral neuropathy; visual disturbances are not a common adverse effect.</p>\r\n<p><strong>Rifampicin (Option B):</strong> Causes hepatotoxicity, gastrointestinal upset, flu-like syndrome, and orange discoloration of body fluids, but not visual disturbances.</p>\r\n<p><strong>Streptomycin (Option D):</strong> Causes ototoxicity (hearing loss) and nephrotoxicity; visual problems are not typical.</p>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">500 Rupees per month</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">500 Rupees per week</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Mid-day meal daily</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Nutritional dietary advice/counselling</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Nikshay Poshan Yojana includes:</span></p>",
      "unique_key": "DT1230726",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230726,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Nikshay Poshan Yojana is a <strong>financial support scheme</strong> launched by the Government of India under the <strong>Revised National Tuberculosis Control Program (RNTCP)</strong>.</p>\r\n<ul>\r\n<li>Provides <strong>rs.500 per month</strong> to TB patients during the course of treatment.</li>\r\n<li>Aim: To ensure <strong>better nutrition</strong> and <strong>treatment adherence</strong>, especially among <strong>economically disadvantaged patients</strong>.</li>\r\n<li>Mode of assistance: Direct financial benefit transfer to support <strong>nutritional intake</strong> during TB treatment.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>500 Rupees per week (Option B):</strong> Higher than actual scheme amount; the scheme provides rs500 per month, not per week.</p>\r\n<p><strong>Mid-day meal daily (Option C):</strong> Part of a separate program aimed at school children; not related to Nikshay Poshan Yojana.</p>\r\n<p><strong>Nutritional dietary advice/counselling (Option D):</strong> While part of comprehensive TB care, it is not the <strong>primary component</strong> of Nikshay Poshan Yojana, which focuses on financial assistance.</p>",
      "correct_choice_id": 31,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">NIKSHAY</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">NISCHAY</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">e-DOTS</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">NIRBHAI</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which among the following is the NTEP software online to monitor TB control program?</span></p>",
      "unique_key": "DT1230727",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230727,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>NIKSHAY</strong> is the <strong>case-based, web-based IT system</strong> developed by the Central TB Division in collaboration with the National Informatics Centre to monitor TB patients under NTEP.</p>\r\n<ul>\r\n<li>It was launched in <strong>May 2012</strong> and facilitates TB patient registration, diagnosis details, DOT provider information, HIV status, treatment outcomes, and follow-up.</li>\r\n<li>It also enables TB notification from both public and private sectors, transfer/referral of patients, and automated periodic reports for case finding, sputum conversion, and treatment outcome.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>NISCHAY (Option B):</strong> A card test used to confirm pregnancy, not related to TB monitoring.</p>\r\n<p><strong>e-DOTS (Option C):</strong> Electronic Directly Observed Therapy, a virtual method where a healthcare provider observes a patient taking anti-TB drugs via real-time or recorded video; not the main NTEP monitoring software.</p>\r\n<p><strong>NIRBHAI (Option D):</strong> Refers to the Nirbhaya Fund initiative for women's safety; unrelated to TB control programs.</p>",
      "correct_choice_id": 41,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">INH</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Rifampicin</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Streptomycin</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Ethambutol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient is on ATT. She is using OCP as a contraceptive. Which of the following can cause contraceptive failure while using OCP?</span></p>",
      "unique_key": "DT1230728",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230728,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Rifampicin is a potent enzyme inducer that increases the metabolism of oral contraceptive hormones, reducing their effectiveness and increasing the risk of contraceptive failure.</p>\r\n<ul>\r\n<li><strong>Rifampicin</strong> is a potent inducer of hepatic enzymes, particularly cytochrome P450, which are responsible for metabolizing many drugs, including hormonal contraceptives.</li>\r\n<li>It accelerates the metabolism of <strong>oestrogen</strong> and <strong>progestin</strong> in OCPs, reducing their efficacy and increasing the risk of contraceptive failure or unintended pregnancy.</li>\r\n<li>Therefore, concomitant use of rifampicin with OCPs can lead to contraceptive failure.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>INH (Option A):</strong> Does not interfere with the effectiveness of OCPs and does not affect the metabolism of oestrogen or progestin.</p>\r\n<p><strong>Streptomycin (Option C):</strong> An aminoglycoside antibiotic used for TB treatment; no evidence of interaction with OCP metabolism or absorption.</p>\r\n<p><strong>Ethambutol (Option D):</strong> Works by inhibiting mycobacterial cell wall synthesis; does not influence the metabolism of hormonal contraceptives.</p>",
      "correct_choice_id": 52,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">INH & Rifampicin</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">INH, Rifampicin, Kanamycin & Amikacin</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">INH, Rifampicin, Ofloxacin & Pyrazinamide</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">INH, Rifampicin, Amikacin & Levofloxacin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">XDR TB means resistance to:</span></p>",
      "unique_key": "DT1230729",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230729,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>XDR TB is defined as tuberculosis that is resistant to at least <strong>Isoniazid (INH)</strong>, <strong>Rifampicin</strong>, a <strong>fluoroquinolone</strong> (e.g., Levofloxacin), and at least one of the <strong>second-line injectable drugs</strong> (e.g., Amikacin).</p>\r\n<ul>\r\n<li>It is an advanced form of drug resistance developing from MDR-TB.</li>\r\n<li>Resistance to INH and Rifampicin constitutes MDR-TB.</li>\r\n<li>Additional resistance to a fluoroquinolone and a second-line injectable drug escalates it to XDR TB.</li>\r\n<li>XDR TB is associated with <strong>poorer treatment outcomes</strong> and <strong>requires more complex regimens</strong> with fewer effective drugs.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>INH &amp; Rifampicin (Option A):</strong> Refers to MDR-TB, not XDR-TB, as it does not include resistance to fluoroquinolones and second-line injectables.</p>\r\n<p><strong>INH, Rifampicin, Kanamycin &amp; Amikacin (Option B):</strong> Involves two injectable drugs but lacks fluoroquinolone resistance, so it does not fulfill XDR-TB criteria.</p>\r\n<p><strong>INH, Rifampicin, Ofloxacin &amp; Pyrazinamide (Option C):</strong> Includes a fluoroquinolone but lacks resistance to a second-line injectable drug, so it is not classified as XDR-TB.</p>",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Nischay</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Nikshay</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">DOTS</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">MTCS</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Web based program for monitoring TB</span></p>",
      "unique_key": "DT1230730",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230730,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Nikshay is the official <strong>web-based platform</strong> used in India for <strong>monitoring and managing TB cases</strong> under NTEP, making it the correct answer.</p>\r\n<ul>\r\n<li><strong>Developed by:</strong> Government of India under the National TB Elimination Program (NTEP).</li>\r\n<li><strong>Purpose:</strong> Registration of TB patients, recording treatment details, monitoring drug adherence, and generating program performance reports.</li>\r\n<li><strong>Users:</strong> Health workers, clinicians, and program managers.</li>\r\n<li><strong>Benefits:</strong> Ensures real-time tracking, better treatment compliance, and improved patient management.</li>\r\n<li><strong>Functionality:</strong> Facilitates communication between different levels of TB control units and helps in case-based monitoring.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Nischay (Option A):</strong> Not related to TB patient monitoring; unrelated to NTEP software.</p>\r\n<p><strong>DOTS (Option C):</strong> Directly Observed Treatment, Short-Course is a TB treatment strategy, not a web-based platform.</p>\r\n<p><strong>MTCS (Option D):</strong> Mycobacterium tuberculosis Complex Surveillance is a lab-based drug resistance surveillance system, not for patient tracking.</p>",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Repeat sputum microscopy</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">CBNAAT</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Culture</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Give antibiotics</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">According to national tuberculosis guidelines what to do next in sputum negative x-ray positive TB suspect</span></p>",
      "unique_key": "DT1230731",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230731,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>CBNAAT is recommended as the <strong>next step</strong> for sputum-negative but X-ray positive TB suspects as per national guidelines because it is <strong>highly sensitive, rapid, and can also detect rifampicin resistance</strong>.</p>\r\n<ul>\r\n<li><strong>Full form:</strong> Cartridge-Based Nucleic Acid Amplification Test.</li>\r\n<li><strong>Purpose:</strong> Detects Mycobacterium tuberculosis and rifampicin resistance directly from sputum.</li>\r\n<li><strong>When used:</strong> In patients with negative sputum smear but radiological features suggestive of TB.</li>\r\n<li><strong>Advantages over microscopy:</strong> Higher sensitivity, detects drug resistance, provides results within 2 hours.</li>\r\n<li><strong>Place in algorithm:</strong> Recommended after negative sputum microscopy in suspected TB with abnormal CXR.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Repeat sputum microscopy (Option A):</strong> Not recommended as the next step since repeat microscopy has limited additional diagnostic yield in sputum-negative, X-ray positive cases.</p>\r\n<p><strong>Culture (Option C):</strong> Gold standard for TB diagnosis but slower; usually performed if CBNAAT is negative but suspicion remains high, or for detailed drug susceptibility testing.</p>\r\n<p><strong>Give antibiotics (Option D):</strong> Not appropriate without confirmed TB diagnosis; delays correct treatment initiation and risks partial or incorrect therapy.</p>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">CBNAAT</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Interferon gamma assay</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Line probe assay</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Liquid culture</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which test uses whole blood as sample in detection of TB?</span></p>",
      "unique_key": "DT1230732",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230732,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The <strong>Interferon Gamma Release Assay (IGRA)</strong> is the test that uses whole blood as a sample to detect TB infection. It measures interferon gamma released by T-cells in response to TB-specific antigens.</p>\r\n<ul>\r\n<li>Examples include <strong>QuantiFERON-TB Gold test</strong> and <strong>T-SPOT.TB test</strong>.</li>\r\n<li>Works by detecting <strong>immune response</strong> to <em>Mycobacterium tuberculosis</em>.</li>\r\n<li>Uses <strong>whole blood sample</strong> collected from the patient.</li>\r\n<li>Measures <strong>interferon gamma release</strong> from sensitized T-cells after exposure to TB antigens.</li>\r\n<li>Does <strong>not distinguish</strong> between latent and active TB infection.</li>\r\n<li>Useful in individuals with prior BCG vaccination because it avoids cross-reactivity.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>CBNAAT (Option A):</strong> Detects Mycobacterium tuberculosis DNA and rifampicin resistance from sputum or respiratory specimens, not whole blood.</p>\r\n<p><strong>Line probe assay (Option C):</strong> Detects drug resistance patterns from sputum samples or cultured isolates; does not use whole blood.</p>\r\n<p><strong>Liquid culture (Option D):</strong> Grows Mycobacterium tuberculosis in liquid medium from sputum or tissue samples; does not use whole blood.</p>",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">District centre</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">TB unit</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">DMC</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">IRL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which is the most peripheral health institution used for sputum TB examination?</span></p>",
      "unique_key": "DT1230733",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230733,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The <strong>Designated Microscopy Centre (DMC)</strong> is the most peripheral health institution specifically designated for sputum TB examination. It plays a vital role in early case detection and timely initiation of treatment at the community level.</p>\r\n<ul>\r\n<li><strong>Location:</strong> Usually situated at the primary healthcare level, easily accessible to the community.</li>\r\n<li><strong>Function:</strong> Performs sputum smear microscopy for diagnosing TB.</li>\r\n<li><strong>Role in DOTS:</strong> Forms an essential part of the Directly Observed Treatment Short-course (DOTS) strategy for TB control.</li>\r\n<li><strong>Accessibility:</strong> Serves as the first point of contact for patients suspected of TB in peripheral areas.</li>\r\n<li><strong>Importance:</strong> Early diagnosis at the peripheral level reduces diagnostic delays and improves treatment outcomes.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>District centre (Option A):</strong> Primarily an administrative unit overseeing healthcare services in a district; not directly the most peripheral facility for sputum examination.</p>\r\n<p><strong>TB unit (Option B):</strong> Provides TB services at an intermediate level; covers a larger catchment area compared to DMCs.</p>\r\n<p><strong>IRL (Option D):</strong> Intermediate Reference Laboratory; performs advanced TB diagnostics and drug susceptibility testing; not located at the peripheral level.</p>",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Failure</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Lost To Follow Up</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Cured</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Relapse</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">New TB Definitions</span></p>",
      "unique_key": "DT1230734",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230734,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>\"Lost To Follow Up\" is a <strong>new TB definition</strong> used in national TB programs to describe patients who have <strong>interrupted treatment</strong> and whose treatment outcomes are unknown due to their failure to return for scheduled follow-up visits.</p>\r\n<ul>\r\n<li><strong>Definition:</strong> A TB patient whose treatment was interrupted for <strong>1 month or more</strong> after initiation and before completion of treatment, and whose outcome is not known.</li>\r\n<li><strong>Reason for inclusion:</strong> Helps program managers identify and address gaps in patient follow-up and adherence.</li>\r\n<li><strong>Program relevance:</strong> Considered a critical programmatic indicator because these patients are at risk for disease progression, ongoing transmission, and development of drug resistance.</li>\r\n<li><strong>Difference from older terms:</strong> Replaces older terms like \"defaulter\" to improve clarity and reflect patient-centered care language.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Failure (Option A):</strong> Refers to a patient who remains or becomes sputum smear-positive at month 5 or later during treatment despite adherence to an appropriate regimen; not a new definition.</p>\r\n<p><strong>Cured (Option C):</strong> Refers to a patient who has completed treatment and has negative sputum smear and/or culture results at the end of treatment and on at least one previous occasion; a standard treatment outcome, not a new definition.</p>\r\n<p><strong>Relapse (Option D):</strong> Refers to recurrence of TB in a patient who was previously declared cured or completed treatment, confirmed microbiologically; an established term, not a new definition.</p>",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">InhA gene</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">RpoB gene</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">KatG</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">pncA gene</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">GeneXpert diagnoses drug resistance to TB because of which mutation?</span></p>",
      "unique_key": "DT1230735",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230735,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>GeneXpert detects <strong>rifampicin resistance</strong> by targeting specific mutations in the <strong>RpoB gene</strong> of Mycobacterium tuberculosis.</p>\r\n<ul>\r\n<li>Rifampicin resistance is most often linked to mutations in the <strong>Rifampicin Resistance Determining Region (RRDR)</strong> of the RpoB gene.</li>\r\n<li>Detection of rifampicin resistance is highly predictive of <strong>multidrug-resistant TB (MDR-TB)</strong>.</li>\r\n<li>The test is rapid, highly sensitive, and specific, making it an essential tool in TB control programs.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>InhA gene (Option A):</strong> Associated with isoniazid resistance, not targeted by GeneXpert for drug resistance detection.</p>\r\n<p><strong>KatG (Option C):</strong> Mutations cause isoniazid resistance, but GeneXpert focuses on RpoB mutations for rifampicin resistance detection.</p>\r\n<p><strong>pncA gene (Option D):</strong> Associated with pyrazinamide resistance; not a target of GeneXpert testing.</p>\r\n<p><strong>Reference</strong>:</p>\r\n<p><a title=\"Mutational Frequencies in Mycobacterial rpoB gene using GeneXpert/MTB Rif Assay in Rifampicin Resistant patients at a tertiary care setting in Urban Sindh, Pakistan: Analysis from a Five-Year Period - PMC (nih.gov)\" href=\"Mutational%20Frequencies in Mycobacterial rpoB gene using GeneXpert/MTB Rif Assay in Rifampicin Resistant patients at a tertiary care setting in Urban Sindh, Pakistan: Analysis from a Five-Year Period - PMC (nih.gov)\" target=\"_blank\">Mutational Frequencies in Mycobacterial rpoB gene using GeneXpert/MTB Rif Assay in Rifampicin Resistant patients at a tertiary care setting in Urban Sindh, Pakistan: Analysis from a Five-Year Period - PMC (nih.gov)</a></p>",
      "correct_choice_id": 122,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">INH</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Kanamycin</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Pyrazinamide</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Acyclovir</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Second line ATT is</span></p>",
      "unique_key": "DT1230736",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230736,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Kanamycin is a <strong>second-line anti-tuberculosis drug</strong> used mainly for the treatment of <strong>multidrug-resistant tuberculosis (MDR-TB)</strong> and <strong>extensively drug-resistant tuberculosis (XDR-TB)</strong>. It belongs to the <strong>aminoglycoside</strong> group and is effective against bacilli resistant to INH and rifampicin.</p>\r\n<ul>\r\n<li><strong>Classification:</strong> Second-line injectable aminoglycoside.</li>\r\n<li><strong>Mechanism of action:</strong> Inhibits protein synthesis in mycobacteria.</li>\r\n<li><strong>Indication:</strong> Used when first-line drugs fail due to resistance or intolerance.</li>\r\n<li><strong>Role in NTEP:</strong> Part of the drug regimen for MDR-TB and XDR-TB patients as per guidelines.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>INH (Option A):</strong> First-line anti-TB drug; not classified as a second-line agent.</p>\r\n<p><strong>Pyrazinamide (Option C):</strong> First-line anti-TB drug; used in the initial intensive phase; not a second-line drug.</p>\r\n<p><strong>Acyclovir (Option D):</strong> Antiviral drug used for herpes virus infections; not used in TB management.</p>",
      "correct_choice_id": 132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Start ART first followed by ATT</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Start ATT first followed by ART</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Start ART and ATT together</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">None</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient diagnosed to have both HIV and TB, which of the drug regimens should be followed?</span></p>",
      "unique_key": "DT1230737",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230737,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>In HIV-TB co-infection, <strong>anti-tuberculosis treatment (ATT) should be initiated first</strong> before starting antiretroviral therapy (ART) to reduce the risk of immune reconstitution inflammatory syndrome (IRIS). ART is introduced <strong>after a minimum of 2 weeks</strong> of ATT initiation.</p>\r\n<ul>\r\n<li><strong>Rationale for ATT before ART:</strong>\r\n<ul>\r\n<li>In patients with both HIV and TB, TB symptoms may be less prominent due to <strong>low CD4 counts</strong> and reduced cellular immunity.</li>\r\n<li>If ART is started first, the rapid improvement in immunity can lead to an <strong>exaggerated inflammatory response</strong> against Mycobacterium tuberculosis, known as <strong>IRIS</strong>, which can worsen TB symptoms and increase morbidity.</li>\r\n<li>Starting ATT first allows control of the mycobacterial load before immune restoration occurs.<br /> </li>\r\n</ul>\r\n</li>\r\n<li><strong>IRIS (Immune Reconstitution Inflammatory Syndrome):</strong>\r\n<ul>\r\n<li>Occurs due to restoration of pathogen-specific immune responses after ART initiation.</li>\r\n<li>Presents with fever, worsening TB lesions, lymphadenopathy, respiratory symptoms, and systemic inflammation.<br /> </li>\r\n</ul>\r\n</li>\r\n<li><strong>Timing of ART after ATT:</strong>\r\n<ul>\r\n<li>ART should be initiated <strong>at least 2 weeks after ATT</strong> in most patients.</li>\r\n<li>In patients with very low CD4 counts (&lt;50 cells/mm&sup3;), ART may be started earlier (within 2 weeks) to reduce HIV-related mortality, but with close monitoring for IRIS.<br /> </li>\r\n</ul>\r\n</li>\r\n<li><strong>Drug interaction consideration:</strong>\r\n<ul>\r\n<li>Rifampicin reduces plasma concentrations of <strong>Dolutegravir (DTG)</strong> by inducing hepatic metabolism.</li>\r\n<li>When using rifampicin with DTG, an <strong>additional 50 mg dose of DTG should be taken 12 hours after the standard dose</strong>.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Start ART first followed by ATT (Option A):</strong> This can precipitate IRIS and worsen TB-related inflammation; not recommended.</p>\r\n<p><strong>Start ART and ATT together (Option C):</strong> This increases pill burden, drug-drug interactions, and IRIS risk; not preferred unless under specific urgent circumstances.</p>\r\n<p><strong>None (Option D):</strong> Incorrect, as there is a clear evidence-based sequence, ATT before ART.</p>",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Joint TB Monitoring Mission 2017</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">National Strategic Plan for TB (2017-2025)</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Standards of TB Care</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">National AIDS Control Organisation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The Detect-Treat-Prevent-Build approach for eliminating TB in India is part of the -</span></p>",
      "unique_key": "DT1230752",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230752,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The <strong>Detect-Treat-Prevent-Build</strong> (DTPB) approach is a core strategic framework under the National Strategic Plan (NSP) for TB Elimination (2017-2025).</p>\r\n<ul>\r\n<li><strong>Detect:</strong> Intensified case finding, early diagnosis, and universal drug-susceptibility testing.</li>\r\n<li><strong>Treat:</strong> Prompt initiation and adherence to appropriate treatment regimens.</li>\r\n<li><strong>Prevent:</strong> Measures to reduce TB transmission, address latent TB infection, and prevent drug resistance.</li>\r\n<li><strong>Build:</strong> Strengthen policies, health systems, human resources, and provide adequate financial resources.</li>\r\n<li>The NSP aims to achieve the target of a <strong>TB-free India by 2025</strong>, in alignment with the End TB Strategy and Sustainable Development Goals.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Joint TB Monitoring Mission 2017 (Option A):</strong> Focuses on reviewing program performance and providing recommendations; it does not define the DTPB strategy.</p>\r\n<p><strong>Standards of TB Care (Option C):</strong> Provides guidelines for TB diagnosis, treatment, and care, but does not encompass the NSP's strategic elimination framework.</p>\r\n<p><strong>National AIDS Control Organisation (Option D):</strong> Manages HIV/AIDS programs; while TB-HIV coordination exists, the DTPB strategy is not under NACO's mandate.</p>",
      "correct_choice_id": 152,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary TB</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">CNS and disseminated TB</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary and CNS TB</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary and skeletal TB</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The BCG vaccine provides protection against-</span></p>",
      "unique_key": "DT1230754",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230754,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The BCG (Bacille Calmette-Gu&eacute;rin) vaccine provides its highest level of protection against severe forms of tuberculosis, such as TB meningitis (CNS TB) and disseminated TB, particularly in infants and young children. Its efficacy in preventing pulmonary TB is variable, but it is highly effective in preventing these life-threatening extrapulmonary forms.</p>\r\n<ul>\r\n<li><strong>Aim of BCG vaccination:</strong> To induce artificial primary infection with a mild strain to confer protection against severe TB.</li>\r\n<li><strong>Protection:</strong>\r\n<ul>\r\n<li>Best protection against <strong>TB meningitis</strong> (CNS TB) and <strong>disseminated TB</strong> in children.</li>\r\n<li>Variable efficacy for <strong>pulmonary TB</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>WHO recommendation:</strong> Universal BCG vaccination at birth in high-burden countries to prevent severe childhood TB.</li>\r\n<li><strong>Protective value:</strong> Studies show up to 80% efficacy against TB meningitis and disseminated TB in children.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Pulmonary TB (Option A):</strong> BCG offers variable and lower protection against pulmonary TB compared to CNS and disseminated forms.</p>\r\n<p><strong>Pulmonary and CNS TB (Option C):</strong> While CNS TB protection is strong, pulmonary TB protection is inconsistent.</p>\r\n<p><strong>Pulmonary and skeletal TB (Option D):</strong> Not specifically targeted for skeletal TB prevention; main benefit is for CNS and disseminated TB.</p>",
      "correct_choice_id": 162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">2</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">3</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">4</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">5</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Daily regimen of tuberculosis mandates fixed dose combination (FDC) for both initiation and continuation phases. How many tablets of the following FDCs are to be taken by a normal adult(weight 70 kg) on a daily basis? Intensive phase- 4 FDC(HRZE), (75/150/400/275)Continuation phase- 3 FDC(HRE), (75/150/275)</span></p>",
      "unique_key": "DT1230756",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230756,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>In the NTEP daily regimen, the number of FDC tablets is based on patient weight bands. For adults weighing <strong>66-75 kg</strong>, the schedule mandates:</p>\r\n<ul>\r\n<li><strong>Intensive phase (HRZE)</strong>: 4-drug combination (Isoniazid 75 mg, Rifampicin 150 mg, Pyrazinamide 400 mg, Ethambutol 275 mg) - <strong>5 tablets daily</strong>.</li>\r\n<li><strong>Continuation phase (HRE)</strong>: 3-drug combination (Isoniazid 75 mg, Rifampicin 150 mg, Ethambutol 275 mg) - <strong>5 tablets daily</strong>.</li>\r\n</ul>\r\n<p>Thus, a normal adult weighing <strong>70 kg</strong> requires <strong>5 tablets daily</strong> in both phases.</p>\r\n<p><strong>Weight-band-based adult FDC dosage (NTEP, 2019):</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509252f4e9758-c968-4058-b8cc-8b9d540b4720.PNG\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>2 (Option A):</strong> Matches 2-34 kg weight band, not applicable for 70 kg adult.</p>\r\n<p><strong>3 (Option B):</strong> Matches 35-49 kg weight band, not applicable for 70 kg adult.</p>\r\n<p><strong>4 (Option C):</strong> Matches 50-64 kg weight band, not applicable for 70 kg adult.</p>",
      "correct_choice_id": 174,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">New case</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Previously treated patient</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Treatment after Loss to follow-up</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Recurrent TB case</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">According to NTEP, a TB patient who had taken drugs for three weeks in the past is considered as a:</span></p>",
      "unique_key": "DT1230758",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230758,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>A TB patient who has taken anti-TB drugs for <strong>less than 1 month</strong> in the past is classified as a <strong>New case</strong> under NTEP.</p>\r\n<ul>\r\n<li>Such patients have never undergone a complete course of TB treatment and are started on the standard regimen for new cases.</li>\r\n<li>The classification is important for selecting the correct drug regimen and for programmatic reporting.</li>\r\n</ul>\r\n<p><strong>Key points from NTEP classification:</strong></p>\r\n<ul>\r\n<li><strong>New case:</strong> Never taken TB treatment or taken for &lt;1 month.</li>\r\n<li><strong>Previously treated:</strong> Taken TB treatment for &ge;1 month in the past.</li>\r\n<li><strong>Treatment after loss to follow-up:</strong> Previously treated patient who interrupted treatment for &ge;2 consecutive months.</li>\r\n<li><strong>Recurrent TB case:</strong> Previously treated, declared cured or treatment completed, and now microbiologically confirmed TB again.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Previously treated patient (Option B):</strong> Requires &ge;1 month of prior treatment; not applicable here.</p>\r\n<p><strong>Treatment after Loss to follow-up (Option C):</strong> Applies to patients who interrupted a previous course for &ge;2 months.</p>\r\n<p><strong>Recurrent TB case (Option D):</strong> Applies when TB reoccurs after a patient was cured or completed treatment previously.</p>",
      "correct_choice_id": 181,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Age below 5 years can be included</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Postmenopausal female can be included</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Patients with stable controlled arrhythmia can be included</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Pregnant females are excluded</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All of the following are criteria regarding the Bedaquiline Conditional Access Programme under RNTCP except -</span></p>",
      "unique_key": "DT1230759",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230759,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Bedaquiline (BDQ) is a diarylquinoline antimycobacterial drug used under conditional access for the treatment of MDR-TB and XDR-TB as part of the RNTCP/NTEP guidelines.</p>\r\n<ul>\r\n<li>Children aged <strong>&lt;5 years</strong> are <strong>excluded</strong> from BDQ therapy due to limited safety and efficacy data in this age group.</li>\r\n<li>Other eligibility criteria include age &ge;18 years, confirmed MDR/RR-TB with resistance to fluoroquinolones or second-line injectables, and cases of treatment failure of MDR-TB with FQ/SLI resistance or XDR-TB.</li>\r\n<li><strong>Postmenopausal women</strong> and <strong>patients with stable controlled arrhythmia</strong> may be included after careful assessment.</li>\r\n<li><strong>Pregnancy</strong> is a contraindication for BDQ due to potential fetal risks.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Postmenopausal female can be included (Option B):</strong> Eligible if other criteria are met; menopausal status is not a contraindication.</p>\r\n<p><strong>Patients with stable controlled arrhythmia can be included (Option C):</strong> May be considered with ECG monitoring, as BDQ can prolong QT interval.</p>\r\n<p><strong>Pregnant females are excluded (Option D):</strong> Contraindicated due to potential teratogenic effects and insufficient safety data.</p>",
      "correct_choice_id": 191,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">Dorsum of left arm</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">Dorsum of right arm</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">Ventral aspect of left forearm</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">Ventral aspect of right forearm</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Tuberculin testing is to be done at -</span></p>",
      "unique_key": "DT1230795",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230795,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The Mantoux tuberculin skin test is performed by injecting <strong>1 TU of PPD in 0.1 ml intradermally</strong> on the <strong>flexor (ventral) surface of the left forearm</strong>, midway between the wrist and elbow. This standardized site ensures consistency in administration and interpretation of results. The left forearm is preferred to minimize interference with daily activities, as most individuals are right-handed, and to facilitate accurate follow-up readings.</p>\r\n<ul>\r\n<li><strong>Dose &amp; Site:</strong> 1 TU PPD in 0.1 ml, intradermally, ventral aspect of left forearm.</li>\r\n<li><strong>Technique:</strong> Injection given with a tuberculin syringe, bevel facing upward, producing a pale elevation (wheal) of 6-10 mm.</li>\r\n<li><strong>Reading Time:</strong> 48-96 hours post-injection (standard is 72 hours).</li>\r\n<li><strong>Measurement:</strong> Measure transverse diameter of induration (not erythema).</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Dorsum of left arm (Option A):</strong> Not recommended; dorsum is not a standard site for Mantoux testing due to less uniform skin thickness and difficulty in interpretation.</p>\r\n<p><strong>Dorsum of right arm (Option B):</strong> Not used; dorsum of arm is avoided for the same reasons as Option A.</p>\r\n<p><strong>Ventral aspect of right forearm (Option D):</strong> Though ventral surface is correct, right forearm is not used as standard practice to maintain uniformity and avoid interference with daily activities.</p>",
      "correct_choice_id": 203,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">48 hours</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">72 hours</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">96 hours</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">24 hours</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the ideal time to read the result of Mantoux test?</span></p>",
      "unique_key": "DT1230797",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230797,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The ideal time to read the Mantoux test result is <strong>72 hours after administration</strong>, as this allows the induration to reach its maximum size, ensuring the most accurate interpretation. Although readings can be taken between <strong>48-72 hours</strong>, waiting until 72 hours provides optimal accuracy.</p>\r\n<ul>\r\n<li>The Mantoux test is also called the tuberculin skin test (TST) and is used to detect prior infection with Mycobacterium tuberculosis.</li>\r\n<li>It involves intradermal injection of 1 TU of purified protein derivative (PPD) in 0.1 mL on the ventral aspect of the left forearm.</li>\r\n<li>The immune reaction is measured as <strong>induration</strong> (palpable, raised, hardened area) and not erythema.</li>\r\n<li>Measurement is done perpendicular to the long axis of the forearm in millimetres.</li>\r\n<li>Reading before 48 hours may be too early for the immune response to develop, and after 72 hours the reaction may start to regress.</li>\r\n<li>The correct interpretation depends on patient risk factors and the size of induration according to standard cut-offs.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>48 hours (Option A):</strong> While reading at 48 hours is within the acceptable time frame, the immune response may still be maturing and the induration may not have reached its peak, making 72 hours the ideal.</p>\r\n<p><strong>96 hours (Option C):</strong> Beyond 72 hours, the reaction may start to regress, potentially leading to underestimation of induration and inaccurate interpretation.</p>\r\n<p><strong>24 hours (Option D):</strong> Too early for the immune-mediated induration to develop; reading at this time risks false-negative results.</p>",
      "correct_choice_id": 212,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">Identify all positives to tuberculin test</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Sputum examination of symptomatic patients</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Identify new converter to tuberculin test</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">Screen all under five years children for tuberculin test</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The most appropriate method to assess the incidence of tuberculosis in the community is-</span></p>",
      "unique_key": "DT1230799",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230799,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Identifying <strong>new converters</strong> to the tuberculin skin test is the most appropriate method to assess the incidence of TB in the community, as it detects recent infection and reflects ongoing transmission.</p>\r\n<ul>\r\n<li>A new converter is an individual who changes from a negative to a positive tuberculin skin test (TST) within a defined period.</li>\r\n<li>Conversion usually indicates <strong>recent infection</strong> with Mycobacterium tuberculosis, making these individuals a high-risk group for progression to active TB disease.</li>\r\n<li>This method provides <strong>direct information on incidence</strong> by identifying fresh infections, rather than cumulative prevalence.</li>\r\n<li>Monitoring new converters enables <strong>early intervention</strong>, chemoprophylaxis where indicated, and targeted public health actions to interrupt transmission chains.</li>\r\n<li>Other methods either capture cumulative infection burden or only detect existing active cases, making them less specific for measuring incidence.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Identify all positives to tuberculin test (Option A):</strong> Detects both old and new infections, thus reflecting prevalence rather than incidence; also affected by BCG vaccination and exposure to non-tuberculous mycobacteria.</p>\r\n<p><strong>Sputum examination of symptomatic patients (Option B):</strong> Identifies existing active TB cases but misses asymptomatic latent infections, and therefore does not give a full picture of incidence.</p>\r\n<p><strong>Screen all under five years children for tuberculin test (Option D):</strong> While important for high-risk group surveillance, this approach misses infections in older age groups and is not representative of community-wide incidence.</p>",
      "correct_choice_id": 223,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">Mumbai</span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">Bangalore</span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">Delhi</span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyderabad</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">National Tuberculosis Institute is located in -</span></p>",
      "unique_key": "DT1230801",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230801,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The <strong>National Tuberculosis Institute (NTI)</strong> is located in <strong>Bangalore, Karnataka</strong>, and was established in 1959 by the Government of India to address the problem of tuberculosis. It plays a vital role in <strong>research, training, and development of strategies</strong> for TB control and management in the country.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Mumbai (Option A):</strong> Location of the Tuberculosis Research Centre (TRC), not NTI.</p>\r\n<p><strong>Delhi (Option C):</strong> While it has institutions working on TB control, NTI is not located here.</p>\r\n<p><strong>Hyderabad (Option D):</strong> Houses several medical research institutions, but not NTI.</p>",
      "correct_choice_id": 232,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 25,
      "choices": [
        {
          "id": 241,
          "text": "<p><span style=\"font-size:12.0pt;\">Chennai</span></p>"
        },
        {
          "id": 242,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyderabad</span></p>"
        },
        {
          "id": 243,
          "text": "<p><span style=\"font-size:12.0pt;\">Bangalore</span></p>"
        },
        {
          "id": 244,
          "text": "<p><span style=\"font-size:12.0pt;\">Delhi</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">National Institute of Tuberculosis and Respiratory Diseases is located in -</span></p>",
      "unique_key": "DT1230803",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230803,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The National Institute of Tuberculosis and Respiratory Diseases (NITRD) is located in <strong>Delhi</strong>, India.</p>\r\n<ul>\r\n<li>Established in <strong>1956</strong>, it was earlier known as <strong>Lala Ram Sarup TB Hospital</strong>.</li>\r\n<li>It is a premier institute under the <strong>Ministry of Health and Family Welfare</strong>, dedicated to <strong>research, training, and patient care</strong> in the fields of <strong>tuberculosis and respiratory diseases</strong>.</li>\r\n<li>The institute provides specialised services in <strong>pulmonology, thoracic surgery, microbiology, pathology</strong>, and <strong>radiology</strong>, and serves as a nodal centre for TB control and management.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250925ba4421c0-9820-4ae8-a154-7a7fa0cbb1d1.PNG\">",
      "correct_choice_id": 244,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 26,
      "choices": [
        {
          "id": 251,
          "text": "<p><span style=\"font-size:12.0pt;\">Efavirenz</span></p>"
        },
        {
          "id": 252,
          "text": "<p><span style=\"font-size:12.0pt;\">Lopinavir</span></p>"
        },
        {
          "id": 253,
          "text": "<p><span style=\"font-size:12.0pt;\">Nelfinavir</span></p>"
        },
        {
          "id": 254,
          "text": "<p><span style=\"font-size:12.0pt;\">Ritonavir</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Among the ART drugs, which one is acceptable with rifampicin-based ATT?</span></p>",
      "unique_key": "DT1231250",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231250,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Efavirenz is the preferred antiretroviral drug when co-administered with rifampicin-based antitubercular therapy (ATT).</p>\r\n<ul>\r\n<li><strong>Efavirenz</strong> is a non-nucleoside reverse transcriptase inhibitor (NNRTI).</li>\r\n<li>It undergoes <strong>minimal metabolism by the cytochrome P450 system</strong>, which is induced by rifampicin.</li>\r\n<li>Due to its pharmacokinetic profile, <strong>Efavirenz maintains therapeutic levels even in the presence of rifampicin</strong>, making it safe and effective for co-administration.</li>\r\n<li>It is part of the <strong>preferred first-line ART regimen</strong> in TB-HIV coinfected patients receiving rifampicin.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Lopinavir (Option B):</strong> A protease inhibitor whose levels are significantly reduced by rifampicin due to CYP450 induction, leading to treatment failure.</p>\r\n<p><strong>Nelfinavir (Option C):</strong> Also a protease inhibitor; rifampicin reduces its concentration, hence not suitable for co-administration.</p>\r\n<p><strong>Ritonavir (Option D):</strong> Although it inhibits CYP450 and boosts other PIs, it is not used as a standalone option with rifampicin-based ATT due to complex interactions and insufficient efficacy.</p>",
      "correct_choice_id": 251,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 27,
      "choices": [
        {
          "id": 261,
          "text": "<p><span style=\"font-size:12.0pt;\">Rifampicin, isoniazid and fluoroquinolone</span></p>"
        },
        {
          "id": 262,
          "text": "<p><span style=\"font-size:12.0pt;\">Rifampicin, isoniazid and kanamycin</span></p>"
        },
        {
          "id": 263,
          "text": "<p><span style=\"font-size:12.0pt;\">Rifampicin and kanamycin</span></p>"
        },
        {
          "id": 264,
          "text": "<p><span style=\"font-size:12.0pt;\">Isoniazid and rifampicin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">MDR-TB is defined as resistance to which of the following drugs?</span></p>",
      "unique_key": "DT1231633",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231633,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>MDR-TB (Multidrug-Resistant Tuberculosis) is defined as <strong>resistance to at least isoniazid and rifampicin</strong>, the two most potent first-line anti-TB drugs.</p>\r\n<ul>\r\n<li>This definition is clearly outlined under\"Classification based on drug resistance pattern\" in Park's textbook.</li>\r\n<li>MDR-TB is different from mono-resistance (resistance to a single drug) and poly-resistance (resistance to more than one drug, but not both isoniazid and rifampicin).</li>\r\n<li>Additional resistance to second-line drugs such as fluoroquinolones or injectables like kanamycin would classify the strain as <strong>pre-XDR or XDR-TB</strong>, not MDR-TB.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509256b7a7bcd-1837-4817-86e1-e0a943a96f7a.PNG\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Rifampicin, isoniazid, and fluoroquinolone (Option A):</strong> This pattern indicates progression toward <strong>pre-XDR-TB</strong>, not MDR-TB alone.</p>\r\n<p><strong>Rifampicin, isoniazid, and kanamycin (Option B):</strong> This is also beyond MDR-TB, suggestive of <strong>pre-XDR or XDR-TB</strong>.</p>\r\n<p><strong>Rifampicin and kanamycin (Option C):</strong> This does not meet the definition of MDR-TB since isoniazid resistance is essential.</p>",
      "correct_choice_id": 264,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 28,
      "choices": [
        {
          "id": 271,
          "text": "<p><span style=\"font-size:12.0pt;\">> 10% population of known HIV+ among TB patients tested for HIV in the district</span></p>"
        },
        {
          "id": 272,
          "text": "<p><span style=\"font-size:12.0pt;\">> 12% population of known HIV+ among TB patients tested for HIV in the district</span></p>"
        },
        {
          "id": 273,
          "text": "<p><span style=\"font-size:12.0pt;\">> 15% population of known HIV+ among TB patients tested for HIV in the district</span></p>"
        },
        {
          "id": 274,
          "text": "<p><span style=\"font-size:12.0pt;\">> 20% population of known HIV+ among TB patients tested for HIV in the district</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">As per the NTEP, a high-priority TB-HIV district is defined as:</span></p>",
      "unique_key": "DT1231691",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231691,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>As per NTEP guidelines, a <strong>high-priority TB-HIV district</strong> is one in which <strong>more than 10% of TB patients tested for HIV are found to be HIV-positive</strong>.</p>\r\n<ul>\r\n<li>These districts are targeted for <strong>intensified TB-HIV collaborative activities</strong>, including bi-directional screening, early detection, and integrated care.</li>\r\n<li>The <strong>cut-off of &gt;10% HIV positivity among TB patients</strong> is used to prioritise districts needing enhanced surveillance, resource allocation, and service delivery.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250925d81e8f76-7833-4b7d-ba5a-1adda52f91e7.PNG\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Option B (&gt;12%)</strong>: This exceeds the actual cut-off and is not the standard for defining high-priority districts.</p>\r\n<p><strong>Option C (&gt;15%)</strong>: An arbitrary higher threshold not aligned with NTEP definitions.</p>\r\n<p><strong>Option D (&gt;20%)</strong>: Also incorrect and inconsistent with NTEP classification criteria.</p>",
      "correct_choice_id": 271,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}